Genotoxic events have been known as crucial step in the initiation of cancer. To assess the risk of cancer, genotoxicity assays, including comet, micronucleus (MN), chromosomal aberration, bacterial reverse, and sister chromatid exchange assay, can be performed. Compared with in vitro genotoxicity assay, in vivo genotoxicity assay has been used to verify in vitro assay result As a result, these genotoxicity data may provide meaningful information for the assessment of potential carcinogenicity and for implementation in the prevention of cancer. (J Cancer Prev 2013;18:277-288) 
INTRODUCTION
Cancer is the leading cause of human mortality all over the world. 1 Most cancer tissues show a number of complex chromosomal aberrations. 2, 3 The induction and accumulation of genetic damage can cause genomic instability, and it is known as a crucial step in the generation of cancer. 4 Oncogenicity studies of carcinogenic potential using genotoxicity assays are on the rise. Altered gene expression, abnormal cell growth, and disruption of normal cell function may be related with the genotoxic effects of industrial carcinogens or other potential genotoxic agents.
These phenomenon can result in the genomic instability and possibly carcinogenesis. 1 For evaluating risk of cancer, genetic damage can be determined by genotoxicity assays, including comet assay, micronucleus assay, chromosome aberration assay, gamma-H2AX, and bacterial reverse testing. In this review, the micronucleus assay and the comet assay are focused. 5 Since comet assay takes advantages of speediness, high sensitivity and flexibility for measuring capacity of DNA-strand breakage at the level of individual cells, and micronucleus assay exhibits highly reliable, rapid, and broad-spectrum determination of DNA damage at chromosome level (e.g. screening of chromosomal instability, DNA repair capacity, nuclear division rate, mitogenic response and incidence of necrotic and apoptotic cells). 6 The genotoxicity tests officially approved as the Organi- and evaluating their initial safety while the in vivo assay provides detailed information of biological and physiological significance. It can determine whether any potential mutagenic effects that have shown in the in vitro step have appeared again in the animal's whole physiological system. 5 Consequently, the in vivo assays have been known as important processes in the verification of in vitro test and risk assessments for humans, indicating that they have more impact than in vitro assays.
The comet assay firstly established by Östling and Johanson has been widely applied for studying DNA strand breaks at the single cell level. 9 The in vivo comet assay used to detect the genotoxic potential of chemicals has been recognized as a second in vivo genotoxicity assay by the International Conference on Harmonization (ICH-S2 (R1)) guidance (2012) with in vivo micronucleus (MN) assay. In the field of genotoxicology, the in vivo comet assay has been considered as powerful tools to distinguish between genotoxic carcinogens and nongenotoxic carcinogens as well as to identify carcinogens and mutagens. 10 Consequently, the comet assay can be a biomarker for detecting both genetic susceptibility and the DNA damage related to carcinogenesis. 11, 12 Most carcinomas normally show a greater degree of DNA damage with extensive comet tails than that found in the tissue cells from controls. 13 In several researches, CD-1 mouse strain has been commonly used as standard animal model in the in vivo comet assay.
Beside comet assay, the MN assay has been developed for genotoxicity and mutagenicity detection testing of chemicals that induce the formation of small membrane bound DNA fragments in cells (well-known as micronucleus). [14] [15] [16] In principle, the MN assay is capable of detecting potential genotoxic chemicals that can modify chromosome structure and induce segregation error. 17 In number of researches, standard laboratory strains of animals used in the MN assay are F344 rat, SD rat, and CD-1 mouse. Recent studies using the MN assay have shown that increased MN frequency is related with cancer risk, thus supporting the evidence that MN can be a biomarker of carcinogenesis. 18, 19 As so far application of genotoxicity testing suggests that no single assay can fully detect all genotoxic aspects, 20 the ICH guidance on genotoxicity testing have thus proposed combining the in vivo comet assay with the in vivo MN assay. 21 Measurement of DNA damage using genotoxicity assays has been known as a crucial approach for understanding the carcinogenesis and assessing the risk of cancer incidence. 22, 23 This review will discuss the significance of in vivo comet assay and in vivo MN assay for testing genotoxicity and predicting carcinogenic potential (Fig. 1) . By comparing potential carcinogenicity studies using genotoxicity assays with other carcinogenicity databases, prediction of carcinogenic potential will be discussed in the following section and the development of both in vivo assays of comet assay and micronucleus assay will be further warranted.
PRINCIPLE OF IN VIVO COMET ASSAY
In vivo comet assay has been generally performed to detect DNA strand breaks as the comet tail-like-shapes formed by DNA fragment in cells. In principle, after the lysis and electrophoresis steps of cells, the negatively charged DNA fragments migrate out of the cell toward the anode, and appear in a comet shape visualized under a fluorescence microscope. 24 In a testing for genotoxic carcinogen agents, increased migration of the negatively charged DNA fragments toward the anode indicate increased the numbers of DNA strand breaks. Alkaline version of comet assay was introduced for the detection of double strand breaks, single strand breaks, alkali labile sites, DNA cross-linking, and incomplete excision repair sites. 10, 24 The alkaline-based comet assay has shown increased sensitivity for detecting genotoxic agents because most genotoxic agents may induce more single strand breaks or alkali labile sites than double strand breaks. 25 Overall, the advantages of the comet assay in comparison to other genotoxicity assays include: (1) applicability to various tissues and cell types (flexibility), (2) no number of cells requirement, (3) sensitivity to detecting DNA damage, (4) brevity of performance time, and (5) the relatively low cost of the method. 10, 20, [26] [27] [28] [29] Prior to the establishment of an OECD test guideline, the in vivo comet assay using tissues was established by JaCVAM validation studies.
METHODOLOGY OF IN VIVO COMET ASSAY
Any type of animal tissue (e.g. liver, stomach, and blood cells) can be applied to the in vivo comet assay, as long as the tissue types can provide high-quality single cell suspension. 30 This methodology of comet assay refers to JaCVAM validation studies (Fig. 2) . (% tail DNA/100)]. 31 
In vivo comet assay using stomach tissue
The whole stomach tissue of a sacrificed animal is initially cut opened and washed until free of food residue using an ice-cold mincing buffer. A portion of the forestomach is removed and then discarded, and the glandular stomach is incubated with the ice-cold mincing buffer. After incubation, the surface epithelial layer is gently scraped.
The removed layer is discarded, and the mucosa is rinsed with the ice-cold mincing buffer. Then, the epithelia of the glandular stomach are scraped to obtain cell suspension.
The cell suspension is placed on ice to allow cluster to settle down. Then, the cell suspension of the supernatant can be used to make the comet slides. The cell suspension and low-melting-agarose gel are mixed, and then the cell/agar mixture is dispensed onto the comet slide. 31 As before, the comet slides follow the process of lysis, DNA unwinding, electrophoresis, neutralization, dehydration, DNA staining, and image analysis.
In vivo comet assay using blood sample
Blood sample can be collected by venipuncture. All blood samples must be immediately cooled and processed within 2 hours after collection. The layer made by the blood sample mixed with low-melting-point agarose is placed on the comet slide. As mentioned above, the comet assay is composed of the process of lysis, DNA unwinding, electrophoresis, neutralization, dehydration, staining of comet slide, and image analysis. 32 
PRINCIPLE OF IN VIVO MICRONUCLEUS ASSAY
The micronucleus (MN) can be generally formed by lagging acentric chromosome fragments, acentric chromatid fragments, or whole chromosome that could not included in the daughter nucleus during mitosis telophase because the whole chromosome did not combine with the spindle during the segregation process of anaphase. 15, 17, 33, 34 These chromosome fragments surrounded by nuclear membrane are well known as MN, which is morphologically similar to normal nucleus but smaller in size. 35 Compared to other genotoxicity assays, the MN assay is a quick and easy assay at the data analysis step. Moreover, it has no requirement for metaphase cells, and shows iden- tifiable cells under a fluorescence microscope because each cell has only one nuclear division. 1, 36 The in vivo MN assay was established by the OECD guidelines, and has been continuously being developed through many studies.
METHODOLOGY OF IN VIVO MN ASSAY
The in vivo MN assay is known as simple and sensitive screening method of clastogenic agents in the target tissues (e.g. blood and lung sample). In addition, many studies of in vivo MN assays using tissues have been so far published (Fig. 3) . 37 1. In vivo MN assay using blood sample
The erythrocyte of a blood sample can be collected by bleeding from a blood vessel (e.g. mouse tail vein), cardiac puncture, or large vessel at animal sacrifice. The blood smears are prepared on glass slides and then subsequently stained for microscopy analysis. Using flow cytometry-based analysis, the sample slides should be fixed and stained. DNA-specific staining using acridine orange can exclude the possibility of any artifacts generated by non-DNA-specific staining. 38 
In vivo MN assay using liver tissue
After liver tissues are removed, it is recommended to immediately perfuse the liver tissues with cold saline solution until the blood is completely removed. The final washing uses a cold homogenizing buffer containing EDTA, NaCl, and DMSO. After weighing the liver sample, the tissues are minced, suspended in cold homogenization buffer, and homogenized maintaining in the cold buffer on ice using a potter-type homogenizator. After centrifugation of the homogenate, the supernatant is removed, and the pellet is resuspended in the homogenization buffer.
39
The resuspended pellet needs to be settled down. Then, a drop of the suspension is placed at the end of a pre-cleaned, grease-free, microscopic slide. Subsequently, the drop is spread into a single cell layer without damaging the cell morphology, using a clean cover glass held at 45 degrees. 39, 40 Next, the prepared slides are air dried and then stained by May-Grunwald stain, followed by a Giemsa solution stain. provided reliable data on human carcinogenicity. 44 Table 1 presented the results of the in vivo comet and MN assay that have investigated the genotoxicity of potential carcinogens classified by the IARC in carcinogenicity database. Consequently, the genotoxicity results may enable researchers to predict the carcinogenic potential of chemicals (Table 1) .
For a more comprehensive investigation of genotoxicity in animal models, the National Toxicology Program (NTP) has performed a combined assay using in vivo comet and MN assay. 46 As the comet assay has been known to detect most carcinogens that have been identified as equivocal or negative in the MN assay, the results of both assays are considerably regarded as complementary issue. Therefore, the combined in vivo genotoxicity assay has been recommended to investigate genotoxic potential in several recent studies. [46] [47] [48] In addition, the combined in vivo genotoxicity assay has been regarded as a useful methodology for evaluation of genetic hazard in safety risk assessment because it offers two distinct genotoxicity endpoints. Based on the advantages of the combined in vivo genotoxicity assay, the NTP has introduced this combined assay as a part of detecting the genotoxicity of substances with public health concern. 46 In both in vivo comet and MN assay, mouse strains of BALB/c, C57BL/6, CD-1, ddy, NMRI and White Swiss, and rat strains of F344, SD, and Wistar have been extensively used. In particular, CD-1 mouse strain has been mainly used in the comet assay while strains of F344 rat and SD rat have been frequently used in the MN assay.
The genotoxicity assays have been used for studying the carcinogenesis of chemicals and assessing the potential carcinogenicity of chemicals to humans. 44 The findings based on comet assay and MN assay have shown correlations between genotoxicity and preneoplastic/neoplastic changes. The in vivo comet assay studies have been performed to assess genotoxicity in terms of cancer development. 7 In addition, correlations between MN induction and cancer development have been reported in several studies. 49 Indeed, MN has been known as a manifestation of chromosomal instability that occurs in cancer. 35 Numerous studies focused on the application of MN have shown a significant increase of the MN frequency in peripheral blood lymphocytes of cancer patients in comparison with healthy control patients. 50 These studies have suggested that increased results of the MN frequency are related with an early step in carcinogenesis. In addition, another study utilized the benchmark dose Taken together, these recommendations provide an effective methodology for combining the in vivo comet and MN assays and for interpreting assay data. This approach 
